Efficacy of Propranolol in Traumatic Brain Injury Patients Admitted to the ICU: A Prospective, Randomized, Triple-Blind Study
A legfontosabb adatok
- Ki végzi
- Fundació d'investigació Sanitària de les Illes Balears
- Hol
- Spanyolország6 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 536 fő, tervezett
- Kezdés
- 2026. jún. 1.
- Várható befejezés
- 2028. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Propranolol + Placebo
- A regiszteradat frissítve
- 2026. október 27.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged 18 to 80 years (inclusive) who have sustained a moderate or severe traumatic brain injury (GCS 3-13) and require ICU admission
- Signing of the informed consent by the patient or their legal representative, in the event that the patient is unable to do so
- Before starting the trial, the patient must be hemodynamically stable, defined as having a systolic blood pressure (SBP) of 110 mmHg or higher, a cerebral perfusion pressure (CPP) of 60 mmHg or higher (for patients with ICP monitoring), and a heart rate (HR) of 60 beats per minute or higher. Patients meeting these hemodynamic parameters while receiving a noradrenaline dose lower than 0.10 µg/kg/min may be included
- Initiation of the study within the first 96 hours following the trauma
Ki nem vehet részt
- Patients receiving home treatment with digoxin, diltiazem, or verapamil
- Patients treated with beta-blockers prior to admission
- Patients unable to take medication orally due to swallowing difficulties, and for whom the placement of a nasogastric tube is not indicated
- Hemodynamically unstable patients, defined as having a systolic blood pressure of 109 mmHg or less, a cerebral perfusion pressure of 59 mmHg or less (in patients with ICP monitoring), and a heart rate of 59 beats per minute or less, and requiring a noradrenaline dose greater than 0.10 µg/kg/min
- Lactic acid >2 mmol/L at the time of randomization
- Pre-existing heart disease that contraindicates beta-blockers, such as first-, second-, or third-degree heart block without a permanent pacemaker; heart failure defined as an ejection fraction of less than 40%
- Patients with intolerance to any of the excipients contained in the propranolol or placebo capsules: lactose, calcium carboxymethylcellulose, gelatin (E441), magnesium stearate, hypromellose (E464), glycerol (E422), titanium dioxide (E171), carmine (E120), or sodium carboxymethylcellulose
- Age 17 years or younger, or 81 years or older (inclusive)
- Patients with a TBI of more than 96 hours' duration
- Polytrauma patients with an extracranial Injury Severity Score greater than 18 points or an extracranial AIS score of ≥4 in any region
- Patients with penetrating traumatic brain injury
- Pre-existing asthma or bronchospasm
- Patients with spinal cord injuries
- Patients with both dilated pupils upon admission
- Patients with a poor prognosis and a life expectancy inferior to 24 hours
- Pregnant or breastfeeding women (a pregnancy test is required before inclusion in the clinical trial)
- Patients for whom follow-up at one month and six months cannot be guaranteed
- Patients enrolled in another clinical trial
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Spanyolország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Beta-blockers have shown promise as a treatment to improve patient prognosis following traumatic brain injury (TBI), although the exact mechanism by which they might confer this benefit remains unknown.
A teljes eredeti leírásKevesebb
At the clinical level, several retrospective cohort studies, prospective cohort studies, small prospective clinical trials, and various reviews and meta-analyses suggest that beta-blockers may be associated with an improved prognosis in patients with TBI. Furthermore, the optimal timing, dosage, and duration of beta-blocker treatment remain uncertain. This means there is still uncertainty regarding the overall efficacy of beta-blockade in patients with TBI, as well as the specifics of patient selection, drugs, dosages, routes of administration, and physiological targets.
In summary, the use of beta-blockers in patients with TBI appears to be associated with reduced mortality at the time of ICU discharge, as well as better long-term functional outcomes. However, the lack of high-quality scientific evidence clearly limits the ability to make a generalized recommendation regarding the use of beta-blockers in these patients. Therefore, further clinical trials are needed to analyze the effect of beta-blockers on mortality and short- and long-term functional outcomes in patients with TBI admitted to an Intensive Care Unit (ICU).
A vizsgálat 2 csoportja
- PlaceboPlacebo, összehasonlításként
Patients with TBI admitted to these hospitals who meet the inclusion/exclusion criteria will be randomized to receive propranolol or placebo, administered orally or via nasogastric tube, for 14 days.
Kezelés: Propranolol + Placebo
- PropranololA vizsgált kezelés
Patients with TBI admitted to these hospitals who meet the inclusion/exclusion criteria will be randomized to receive propranolol or placebo, administered orally or via nasogastric tube, for 14 days. The propranolol dosages used are those typically employed in the ICU: treatment begins with an initial dose of 10 mg every 6 hours (40 mg/day), which may be increased to a maximum of 40 mg every 4 hours (maximum 240 mg/day) based on blood pressure and heart rate parameters.
Kezelés: Propranolol + Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Kérdések a feltételekről
- Forrás: NCT07899164: ki vehet részt
- A regiszteradat frissítve
- 2026. október 27.